journal article·2021-04-02Open access

Modeling Dendritic Cell Pulsed Immunotherapy for Mice with Melanoma—Protocols for Success and Recurrence

Juan Carlos Chimal-Eguia, Erandi Castillo-Montiel, Julio Cesar Rangel-Reyes, Ricardo Teodoro Paez-Hernández

Applied Sciences· Volume 11· Issue 7

Abstract

Nowadays, immunotherapy has become an important alternative to fight cancer. One way in which biologists and medics use immunotherapy is by injecting antigen-incubated Dendritic Cells (DCs) into mice to stimulate an immune response. The DCs optimal quantities and infusion times for a successful cancer eradication are often unknown to the therapists; usually, these quantities are obtained by testing various protocols. The article shows a model of five differential equations which represents some interactions between some cells of the immune system and tumor cells which is used to test different infusion protocols of Dendritic Cells. This study aims to find operation ranges to DCs quantities and injection times for which the therapy reduces the tumor significantly. To that end, an exhaustive search of operative protocols is performed using simulations of a mathematical model. Furthermore, nonlinear analysis of the model reveals that without the DC therapy tumor cells cannot stay under non-lethal bounds. Finally, we show that a pulsed periodic therapy can prevent tumor relapsing when the doses and period times lie within a certain range.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · Mathematical Biology Tumor Growth · Cancer Immunotherapy and Biomarkers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Lab. Simulación y Modelado, Centro de Investigación en Computación (CIC) del Instituto Politécnico Nacional, IPN, Av. Miguel Othon de Mendizabal s/n. Col. La Escalera, Mexico City 07738, Mexico

Department of Técnologias WEB, Instituto Politécnico Nacional (IPN)—Centro Nacional de Cálculo (CENAC), Av. Luis Enrique Erro S/N, Unidad Profesional Adolfo López Mateos, Zacatenco, Del. Gustavo A. Madero, Mexico City 07738, Mexico

Área de Física de Procesos Irreversibles, Departamento de Ciencias Básicas, Universidad Autónoma Metropolitana, U-Azcapotzalco, Av. San Pablo 180, Col.Reynosa, Mexico City 02200, Mexico

References (34)

Show source-provided references
1. Dendritic cell—Based immunotherapy: State of the art and beyond10.1158/1078-0432.CCR-15-1399 ↗
2. Recent advances in the field of anti-cancer immunotherapy10.1016/j.bbacli.2015.04.001 ↗
3. Plasmacytoid Dendritic Cells as Cell-Based Therapeutics: A Novel Immunotherapy to Treat Human Immunodeficiency Virus Infection?10.3389/fcimb.2020.00249 ↗
4. Raggi, F., and Bosco, M.C. (2020). Targeting Mononuclear Phagocyte Receptors in Cancer Immunotherapy: New Perspectives of the Triggering Receptor Expressed on Myeloid Cells (TREM-1). Cancers, 12.10.3390/cancers12051337 ↗
5. T Cell Receptor Engineered Lymphocytes for Cancer Therapy10.1002/cpim.97 ↗
6. Adjunct immunotherapies for the management of severely ill COVID-19 patients10.1016/j.xcrm.2020.100016 ↗
7. Improvement of the synthetic tri-peptide vaccine (S3Pvac) against porcine Taenia solium cysticercosis in search of a more effective, inexpensive and manageable vaccine10.1016/j.vaccine.2006.10.018 ↗
8. GK-1 Improves the Immune Response Induced by Bone Marrow Dendritic Cells Loaded with MAGE-AX in Mice with Melanoma
9. Cancer immunotherapy via dendritic cells10.1038/nrc3258 ↗
10. Cancer vaccines: On the threshold of success10.1517/14728214.13.2.295 ↗
11. Dendritic cells in cancer immunotherapy10.1002/eji.201040630 ↗
12. B16 as a Mouse Model for Human Melanoma
13. Dendritic cells in cancer immunotherapy clinical trials: Are we making progress?10.3389/fimmu.2013.00454 ↗
14. Mouse model for Pre-Clinical study of human cancer immunotherapy10.1002/0471142735.im2001s108 ↗
15. Cancer vaccines: Accomplishments and challenges10.1016/j.critrevonc.2008.02.010 ↗
16. Yoshimura, A., and Muto, G. (2010). TGF-β function in immune suppression. Negative Co-Receptors and Ligands, Springer.10.1007/82_2010_87 ↗
17. Enhancing dendritic cell immunotherapy for melanoma using a simple mathematical model
18. Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics10.1007/s00262-007-0387-z ↗
19. Improving T-cell immunotherapy for melanoma through a mathematically motivated strategy: Efficacy in numbers?10.1097/CJI.0b013e318236054c ↗
20. A model of dendritic cell therapy for melanoma10.3389/fonc.2013.00056 ↗
21. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)10.1016/j.ejca.2008.10.026 ↗
22. Schättler, H., and Ledzewicz, U. (2015). Optimal Control for Mathematical Models of Cancer Therapies, Springer.10.1007/978-1-4939-2972-6 ↗
23. Strogatz, S.H. (2014). Nonlinear Dynamics and Chaos: With Applications to Physics, Biology, Chemistry, and Engineering, Westview Press.
24. A mathematical model of periodically pulsed chemotherapy: Tumor recurrence and metastasis in a competitive environment10.1007/BF02460591 ↗
25. A theoretical analysis of interval drug dosing for cell-cycle-phase-specific drugs10.1016/0025-5564(92)90053-Y ↗
26. Periodically pulsed immunotherapy in a mathematical model of tumor-immune interaction10.1142/S0218127413500685 ↗
27. Modeling immunotherapy of the tumor—Immune interaction10.1007/s002850050127 ↗
28. A modified numerical method for bifurcations of fixed points of ODE systems with periodically pulsed inputs10.1016/j.amc.2014.03.054 ↗
29. Real-time cell cycle imaging during melanoma growth, invasion, and drug response10.1111/pcmr.12274 ↗
30. A mathematical model of tumor-immune evasion and siRNA treatment
31. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-210.1007/s002620050405 ↗
32. TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance10.1016/j.ccr.2005.10.012 ↗
33. Glioblastoma, transforming growth factor-β, and Candida meningitis: A potential link10.1016/0002-9343(92)90075-M ↗
34. Determining control parameters for dendritic cell-cytotoxic T lymphocyte interaction10.1002/eji.200425085 ↗